Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ICH-ADAPT II: Aggressive vs Conservative BP in ICH
NCT02281838Phase 2Terminated
- Sponsor
- University of Alberta
- Start
- Aug 2011
- Primary completion
- Nov 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of enalapril, labetalol and hydralazine in intracerebral hemorrhage (ICH) (2 arms), sponsored by University of Alberta. Primary endpoint: Diffusion-weighted imaging (DWI) lesion frequency at 48 hours. Started Aug 2011; status: terminated.
02
Drugs
enalaprillabetalolhydralazine
03
Conditions
intracerebral hemorrhage (ICH)
Beyond the preview
Go deeper on NCT02281838.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02281838.